Study | Type of study | No. CYC-untreated (CYC−) patients with SLE | Measure of ovarian reserve AMH AFC OV | Results | Comments | ||
Gasparin et al9 | Case-control | 40 | √ | – | – | Comparable AMH levels in SLE/CYC− and control groups. | |
Gao et al10 | Case-control | 40 | √ | – | – | AMH of SLE/CYC− group was significantly lower than in control group (p<0.001). | AMH was negatively correlated with disease activity (SLEDAI) (p=0.033). AMH concentration in SLE/CYC− group with normal menstruation was higher than SLE/CYC− group with abnormal menstruation (p<0.001). |
Angley et al39 | Cohort | 68 | √ | – | – | SLE/CYC− women were 1.5–1.6 times more likely to have AMH levels <1.0 ng/mL (PR 1.62, 95% CI 0.93 to 2.82) and AMH levels below the 25th percentile as compared with women without SLE (PR 1.55 (95% CI 0.97 to 2.47)). | |
Lawrenz et al38 | Cross-sectional | 33 | √ | – | – | AMH of SLE/CYC− group was significantly lower than in control group (p<0.05). | There was no correlation between AMH and illness duration or disease activity (SLEDAI). |
Ulug et al40 | Cohort | 20 | – | √ | √ | AFC and OV of SLE/CYC− group were significantly lower than in control group (p<0.001, p=0.006, respectively). | Menstrual irregularities significantly higher in SLE/CYC− group than in control group. |
Di Mario et al41 | Cross-sectional | 86 | √ | – | – | Comparable AMH levels in SLE and control groups. |
AFC, antral follicle count; AMH, anti-Müllerian hormone; CYC, cyclophosphamide; OV, ovarian volume; SLEDAI, SLE Disease Activity Index.